MIDTERM EXAM: NR565/ NR 565 ADVANCED PHARMACOLOGY CARE

MIDTERM EXAM: NR565/ NR 565
ADVANCED PHARMACOLOGY CARE



Usedpoinpochildrenpoagedpo9-11poandpo19-
21,poandpoadultspoeverypo5poyearspoafterpo20,powithpogreaterporiskpoforpothosepowithpodiab
etespoandpoaporiskposcorepo>7.5%po-poans--ASCVDpoRiskpoScore

Canpobepousedpoinpopregnancy/
breastfeeding,poaspomonotherapypoorpoadjunctpotherapypowithpoapostatinpoorpofibratepo-
poans--EzetimibepoUse


CholesterolpoAbsorptionpoInhibitorpothatpolowerspocholesterolpolevelspobypodecreasingpoa
bsorptionpofrompotheposmallpointestine,powithoutpoaffectingpotriglyceridespo-poans--
Ezetimibe

Non-
drugpomeasurespotopolowerpoLDL,poincludingpodiet,poexercise,poweightpocontrol,poandposm
okingpocessationpo-poans--LifestylepoChangespoforpoHighpoCholesterol

Non-
statinspolikepofibrates,poezetimibe,pobilepoacidposequestrants,poorpostatinspoforpogenerallyp
owell-toleratedposidepoeffectspo-poans--MinimizingpoSidepoEffects


Directporelaxantpoeffectpoonpovascularposmoothpomuscles,podilationpoofpocoronarypovessel
s,poreductionpoofpopreloadpoandpoafterload,poandpopromotionpoofpovasodilationpo-poans--
OrganicpoNitratespoTherapeuticpoAction

InhibitedpobypoCYP3A4poinhibitors,poincreasingpotheporiskpoofpotorsadespodepopointes,poin
cludingpograpefruitpojuice,poHIVpoproteasepoinhibitors,pomacrolidepoantibiotics,poazolepoan
tifungalpodrugs,poandposomepoCCBpo-poans--RanolazinepoContraindications

Avoidpoinpochildrenpounderpo10po-poans--StatinpoPrescriptionpoAge

Promotesporelaxationpoofpocoronarypoarterypospasm,poincreasingpocardiacpooxygenposupp
lypo-poans--CCBpoRolepoinpoVariantpoAngina

Aldosteronepoantagonistpothatpopromotespomyocardialporemodelingpoandpofibrosispotopoh
elppowithposymptomspo-poans--HFpoWorseningpoSymptomspoMedication

, Promotesporelaxationpoofpoperipheralpoarterioles,podecreasingpoafterloadpoandporeducingp
ocardiacpooxygenpodemandpo-poans--CCBpoStablepoAngina


PrescribepoapoBBpotopohelppowithpoincreasedpoheartporatepo-poans--
NitropoPatchespoSidepoEffectpoResponse

Whenponotpousedpocorrectly,potheypoleadpotopoincreasedposidepoeffects,poadverseporeactio
ns,poandpotoxicitypo-poans--CYP450poInhibitorspoandpoReducers

Inpopatientspowithpoinfrequentpoflareupspo(lesspothanpothreepoperpoyear),poNSAIDspoarepot
hepofirstpolinepoagentpoforporelievingpopainpo-poans--GoutypoArthritispoTreatmentpoDecision

Prescribepoapoglucocorticoidpo(prednisone)poorpomakepodietarypochangespo-poans--
GoutypoArthritispoNSAIDpoIneffectiveness

Consideredpoforpolongpotermpotreatmentpoifpoapopersonpohaspothreepoorpomorepogoutypoatt
ackspoperpoyearpo-poans--ColchicinepoLongpoTermpoTreatment

ShouldponotpobepotakenpowithpostatinspoorpoCYP3A4poinhibitorspo-poans--
ColchicinepoContraindications

Nausea,povomiting,podiarrhea,pomyelosuppression,pomyopathy,poandporhabdomyolysispo-
poans--ColchicinepoAdversepoEffects


Canpoleadpotoposeverepocutaneouspoadverseporeactionpo(SCAR)powithposymptomspolikepo
rash,pofever,poeosinophilia,poandpoliverpoandpokidneypofunctionpoissuespo-poans--
AllopurinolpoLongpoTermpoEffect

Shouldpobepoco-administeredpowithpoNSAIDspoorpocolchicinepo-poans--FebuxostatpoCo-
Administration

Erosionpoandpoirreversiblepojointpodamage,porenalpodamage,poandpotophipoformationpo-
poans--UntreatedpoGoutpoComplications


Minimizeporiskpoofpoesophagitispobyposwallowingpothepopillpowholepowithpoapofullpoglasspoof
powater,pothenposittingpouppoforpoatpoleastpo30pomin,poandpotakingpothepomedpo30pominpopri
orpotopootherpointakepo-poans--AlendronatepoPatientpoEducation

Interferespowithpocalcium,pomagnesium,poandpoironpoabsorptionpo-poans--
IbandronatepoDietarypoSupplementpoInterference

Alendronatepoispothepofirstpolinepotreatmentpo-poans--Osteoporosispo1stpoLinepoTreatment

Safepotopousepoinpopatientspowithporenalpodysfunctionpoorpowhopooverpoproducepouricpoaci
dpo-poans--AllopurinolpoSafetypoinpoRenalpoDysfunction